MHRA response to the Lancet HRT and breast cancer study link.
Key findings of meta-analysis of participant data from the Collaborative Group on Hormonal Factors in Breast Cancer, published in The Lancet in August 2019, are provided in this article. Prescribers are asked to discuss the new information on the risk of breast cancer with women using or contemplating using HRT at their next routine appointment. The MHRA also sent this advice to healthcare professionals in an alert via the Central Alerting System.
The MHRA wrote:
New data have confirmed that the risk of breast cancer is increased during use of all types of HRT, except vaginal estrogens, and have also shown that an excess risk of breast cancer persists for longer after stopping HRT than previously thought. Prescribers of HRT should discuss the updated total risk with women using HRT at their next routine appointment.